Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis | Zendy

Tülay Şimşek | Zendy; Nilgün Yıldırım | Zendy; Belgi̇n Efe | Zendy; Nur Kebapçı | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis

Author(s) -

Tülay Şimşek,

Nilgün Yıldırım,

Belgi̇n Efe,

Nur Kebapçı

Publication year - 2017

Publication title -

turkish journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.654

H-Index - 10

eISSN - 2147-2661

pISSN - 1300-0659

DOI - 10.4274/tjo.26780

Subject(s) - rituximab , medicine , psoriasis , cd20 , therapeutic modalities , dermatology , graves' disease , monoclonal , disease , graves' ophthalmopathy , monoclonal antibody , immunology , antibody

Management of Graves' orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves' orbitopathy. Here we report a case of a 49-year-old woman with Graves' orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart. Although there was improvement in inflammatory signs of the disease, proptosis did not change after the treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research